电子邮箱：liunli@xzhmu.edu.cn

刘念礼，博士，副教授，硕士生导师。本科毕业于湖南农业大学，2015年博士毕业于湖南大学，同年加入徐州医科大学肿瘤生物治疗研究所。从事肿瘤信号转导研究，研究肿瘤发生发展及耐药的分子机制，以第一作者或参与作者在PNAS，Cancer Letters, Cell Death& Disease, Virology等杂志发表SCI论文20余篇。目前作为主持人获得国家自然科学基金2项。

代表论文：

1.N Liu#, J Ji#, H Qiu, Z Shao, X Wen, A Chen, S Yao, X Zhang, H Yao*, L Zhang*. Improving radio-chemotherapy efficacy of prostate cancer by co-deliverying docetaxel and dbait with biodegradable nanoparticles. 2020, Artificial Cells, Nanomedicine, and Biotechnology 48 (1), 305-314.

2.N Liu#, Z Wu#, A Chen, Y Wang, D Cai, J Zheng, Y Liu, L Zhang. SNRPB promotes the tumorigenic potential of NSCLC in part by regulating RAB26. 2019, Cell death & disease 10 (9), 1-11.

3.NLiu#, Z Wu#, A Chen, D Chai, L Li, L Zhang*, J Zheng*. ISG12a and its interaction partner NR4A1 are involved in TRAIL‐induced apoptosis in hepatoma cells. Journal of cellular and molecular medicine. 2019, Journal of cellular and molecular medicine 23 (5), 3520-3529.

4.X Zhang#,N Liu#, Z Shao, H Qiu, H Yao, J Ji, J Wang, W Lu, RC Chen*, L Zhang*. Folate-targeted nanoparticle delivery of androgen receptor shRNA enhances the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomedicine: Nanotechnology, Biology and Medicine 13 (4), 1309-1321, 2017.

5.N Liu, T Chen, X Wang, D Yang, B Xue, H Zhu*. Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells. 2015, FEBS letters 589 (8), 897-903.

6.N Liu, C Zuo, X Wang, T Chen, D Yang, J Wang, H Zhu*. miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. 2014, Oncotarget 5 (13), 4959-4971.

7.N Liu#, Y Long#, B Liu#, D Yang, C Li, T Chen, X Wang, C Liu, H Zhu*. ISG12a mediates cell response to Newcastle disease viral infection. 2014, Virology 462, 283-294.